Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing

() -- Andrew Callos, Executive Vice President, Chief Commercial Officer, on July 01, 2026, sold 15,000 shares in Cytokinetics (CYTK) for $1,287,000. Following the Form 4 filing with the SEC, Callos has control over a total of 58,555 common shares of the company, with 58,555 shares held directly. SEC Filing: Copyright © 2026. All rights reserved. does not provide investment advice. Unauthorized reproduction is strictly prohibited.